Vima Therapeutics

Executive Summary

Vima Therapeutics is a preclinical biotechnology company dedicated to developing small molecule therapies for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS). Leveraging insights into cellular stress response pathways, the company aims to promote neuroprotection and neuronal repair. Founded in 2018 and headquartered in San Diego, Vima has raised approximately $60 million in funding, positioning it to advance its lead program toward clinical development. The company's approach targets fundamental mechanisms of neurodegeneration, offering potential disease-modifying benefits beyond symptomatic relief. Vima's lead program is currently in preclinical development, with efforts concentrated on completing IND-enabling studies. While the company remains private and has not yet disclosed a specific timeline for clinical entry, the advancement of its pipeline represents a significant milestone in addressing unmet needs in ALS and related disorders. The neurodegenerative disease landscape is highly competitive, but Vima's focus on small molecules and stress pathway modulation differentiates it from gene and cell therapy approaches. Successful progression to clinical trials could unlock substantial value, though preclinical to clinical translation carries inherent risks.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data Release70% success
• Q4 2026IND Filing for Lead ALS Program50% success
• Q1 2027Series B Financing Round60% success